Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491658 | 1.00 | TSHR (0.48) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL20260209 | 0.82 | TSHR (0.41) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL4974578 | 0.80 | ALDH1A1 (0.40) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL29375771 | 0.80 | TSHR (0.48) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL41990 | 0.80 | TSHR (0.48) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL4882904 | 0.79 | TP53 (0.52) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL391628 | 0.78 | CA2 (0.42) | ALDH1A1TDP1CYP3A4TP53MEN1 | |
| SCHEMBL246398 | 0.78 | ENPP2 (0.42) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL31208432 | 0.78 | ENPP2 (0.42) | TSHRALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL1349122 | 0.78 | CYP3A4 (0.48) | ALDH1A1CYP3A4ENPP2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| EP-4727546-A2 | PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE | The Global Alliance for TB Drug Development, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025215450-A1 | THIAZOLE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-10-16 | — | — | WO | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| WO-2025019626-A2 | PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| CN-118974020-A | Substituted 3-aminoindazole derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2024-11-15 | — | — | CN | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-118206427-A | Preparation method of 2,2', 5' -tetrachlorobiphenyl | 上海泰坦科技股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| CN-110573494-B | Novel heterocyclic compound and organic light-emitting device comprising same | 株式会社LG化学 | 2023-05-12 | — | — | CN | disclosed |
| CN-115850021-A | Preparation method of polychlorinated biphenyl standard substance | 上海安谱实验科技股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114835688-A | Substituted 4-aryl imidazole-2-ketone derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-108884059-B | Compound and organic light-emitting element using same | 株式会社LG化学 | 2022-03-18 | — | — | CN | disclosed |
| CN-114174298-A | Pyridazinone pyrimidine derivative and medical application thereof | 正大天晴药业集团南京顺欣制药有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-112011052-B | Functional boron-containing polyarylene sulfide copolymer and preparation method thereof | 四川大学 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | TSHR 4658/4885ALDH1A1 3259/4885HSD17B10 433/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | TSHR 4658/4885ALDH1A1 3259/4885HSD17B10 433/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | TSHR 4658/4885ALDH1A1 3259/4885HSD17B10 433/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | TSHR 4658/4885ALDH1A1 3259/4885HSD17B10 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.